Acromegaly: Historical perspectives and current therapy

Journal of Neuro-Oncology

Volumn 54, Issue 2, 2001, Pages 129-137

  Jane Jr , J A ^a   Thapar, K ^b   Laws Jr , E R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acromegaly; Pituitary neoplasms

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CHLORPROMAZINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GONADORELIN; GONADORELIN ANTAGONIST; GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; LEVODOPA; LISURIDE; MEDROXYPROGESTERONE; OCTREOTIDE; PERGOLIDE; PROLACTIN; QUINAGOLIDE; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; GALLSTONE FORMATION; GASTROINTESTINAL SYMPTOM; HISTORY OF MEDICINE; HUMAN; HUMAN EXPERIMENT; HYPOPHYSIS ADENOMA; INCIDENCE; IRRADIATION; LABORATORY DIAGNOSIS; MORBIDITY; MORTALITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; REMISSION; REVIEW; SURGICAL APPROACH; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; ANIMALS; COMBINED MODALITY THERAPY; HISTORY, 19TH CENTURY; HUMANS; PITUITARY NEOPLASMS;

EID: 0035184356     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012949214960     Document Type: Review

References (111)

1. Sur deux cas d'acromeglie: Hypertophie singuliere, non congenitale, des extremites superieures, inferieures et cephalique
2. Caso singolare di prosopectasia
3. Studii anatomo-patologici sopra un uomo divenuto stranamente deforme per cronica infermita
4. Sur l'anatomie pathologique de l'acromegalie
5. Sull'acromegalia
6. Beitrage zur normalen und pathologischen histologie der menschlichen hypophysis cerebri
7. Partial hypophysectomy for acromegaly: With remarks on the function of the hypophysis
8. The effect of the anterior lobe of the pituitary administered intra-peritoneally upon growth, maturity and oestrus cycle of the rat
9. Notes on a case of acromegaly treated by operation
10. Address in surgery on the technic of operation on the central nervous system
11. Erfolgreiche Operationen eines Hypophentamors auf Nasalem Wage
12. Operat geheilte Akromegalie bei Hypophysentumor
13. The operative treatment of tumors of the hypophysis
14. Remarks on the operative treatment of tumors of the hypophysis. With the report of two cases operated on by an oronasal method
15. Endonasal method of removal of hypohyseal tumors
16. The removal of tumors of the pituitary body by an infranasal route
17. Ein Fall von Hypophysis - Tumor mit operativer Heilung
18. The pituitary adenomata. A follow-up study of the surgical results in 338 cases (Dr Harvey Cushing's series)
19. Cushing's legacy to transsphenoidal surgery
20. Immunoassay of human growth hormone in plasma
21. Preparation of iodine-131I labelled human growth hormone in plasma
22. Studies on human growth hormone: A radioimmunoassay for human growth hormone
23. Heavy particle therapy in acromegaly
24. Pituitary irradiation for acromegaly
25. Treatment of acromegaly with megavoltage radiation therapy
26. Indications for, and results of, treatment of pituitary tumors by external radiation
27. Acromegaly and other disorders of growth hormone secretion
28. Correlative studies of growth hormone and insulin plasma concentrations with metabolic abnormalities in acromegaly
29. Radiation therapy for acromegaly and nonsecretory chromophobe adenomas of the pituitary
30. Conventional pituitary irradiation in acromegaly. Effect on growth hormone and TSH secretion
31. Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly
32. Growth hormone release inhibiting hormone in acromegaly
33. Long-term infusion of growth hormone release inhibiting hormone in acromegaly: Effects on pituitary and pancreatic hormones
34. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
35. Inhibitory effect of L-dopa on GH release in acromegalic patients
36. Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: Homogeneity in the two responses
37. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration
38. Bromocriptine treatment of acromegaly
39. Pituitary ablation in the treatment of diabetic retinopathy
40. Indications of the transsphenoidal approach to pituitary adenomas. Experience with 165 operations
41. Indications for trans-sphenoid approach in neurosurgery. 521 cases
42. Transsphenoidal approach in surgical treatment of pituitary adenomas: General principles and indications in nonfunctioning adenomas
43. Trans-sphenoidal surgery of pituitary fossa tumors with televised radiofluoroscopic control
44. Surgery of the pituitary gland, using the transsphenoidal approach. Comparative study of 2 technical methods
45. Transsphenoidal microsurgery of the normal and pathological pituitary
46. Transsphenoidal hypophysectomy
47. The pathogenesis of acromegaly. Clinical and immunocytochemical analysis in 75 patients
48. Acromegaly
49. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly
50. Epidemiology of acromegaly in the Newcastle region
51. Acromegaly: An epidemiological study
52. Ascertainment and natural history of treated acromegaly in Northern Ireland
53. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984
54. Mortality in acromegaly
55. Anterior pituitary gland
56. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group
57. Acromegaly and colon cancer
58. Mortality and cancer incidence in acromegaly: A retrospective cohort study. United Kingdom Acromegaly Study Group
59. The classification and molecular biology of pituitary adenomas
60. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay
61. An audit of outcome of treatment in acromegaly
62. New developments in the management of acromegaly. Should we achieve absolute biochemical cure?
63. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
64. Criteria for cure of acromegaly: A consensus statement
65. How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors?
66. Conventional supervoltage irradiation is an effective treatment for acromegaly
67. Radiosurgery for growth hormone-producing pituitary adenomas
68. Pituitary surgery for the management of acromegaly
69. Radiosurgery for pituitary tumors and craniopharyngiomas
70. Gamma Knife radiosurgery for functioning pituitary microadenoma
71. Gamma Knife radiosurgery for functioning pituitary adenomas
72. Growth-hormone and prolactin excess
73. Cabergoline in the treatment of acromegaly: A study in 64 patients
74. Treatment of acromegaly with dopamine agonists
75. Cabergoline in acromegaly: A renewed role for dopamine agonist treatment?
76. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly
77. Long-term treatment of acromegaly with bromocriptine
78. Acromegaly. Recognition and treatment
79. Effect of different dopaminergic agents in the treatment of acromegaly
80. Octreotide as primary therapy for acromegaly
81. Octreotide
82. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly
83. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
84. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly
85. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
86. Medical therapy for acromegaly
87. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide
88. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group
89. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly
90. The cardiovascular effects of octreotide treatment in acromegaly: An echocardiographic study
91. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide
92. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients
93. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog)
94. Cardiovascular effects of the somatostatin analog octreotide in acromegaly
95. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly
96. Reversibility of joint thickening in acromegalic patients: An ultrasonography study
97. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
98. In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs
99. Growth hormone receptor antagonists therapy for acromegaly
100. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
101. Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses
102. Endoscopic pituitary tumor surgery
103. Endoscopic endonasal transsphenoidal surgery: Experience with 50 patients
104. Frameless stereotaxy for transsphenoidal surgery
105. Transnasal transsphenoidal approach
106. Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function
107. Transsphenoidal removal of craniopharyngioma
108. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
109. Results of surgical treatment for growth hormone-secreting pituitary adenomas
110. Evidence supporting surgery as treatment of choice for acromegaly
111. Surgical management of acromegaly